Ambu

Earnings Release • Aug 22, 2019

Ambu A/S: Ambu invests into a 100% direct sales organisation for pulmonology in the US

Ambu A/S: Ambu invests into a 100% direct sales organisation for pulmonology in the US

Ambu has decided to invest further and strengthen its largest market by transitioning sales of aScope™ products from the US distributor. As a result, Ambu will move to a 100% direct sales organisation for pulmonary endoscopy in the US. Financial guidance is revised.

Since 2015, Ambu and Tri-anim Health Services, a leading US specialty distributor, have been in partnership to make Ambu’s single-use bronchoscopes the market leader. Today, Tri-anim covers 40% of Ambu’s revenue from sales of aScope™ products within pulmonary endoscopy in the US market. As part of the ongoing initiative to expand our direct sales force, Ambu and Tri-anim have mutually agreed to fully transition the sales of aScope™ products to Ambu.

“We are confident that with our pipeline of new endoscope products in markets including ENT and urology, we will be able to maximise revenue growth and cross-sales effects by going direct. This is an attractive investment for Ambu as transition effects will be outweighed by higher long-term growth,” says CEO of Ambu Juan Jose Gonzalez.

Read more in the attached company announcement.

Contacts

Investor relations

CFO, Michael Højgaard, miho@ambu.com or +45 4030 4349

IR Manager, Nicolai Thomsen, nith@ambu.com or +45 2620 8047

Media

Morten Huse Eikrem-Jeppesen, morten@pressconnect.dk / +45 5385 0770

Attachment

• Company announcement no. 13 2018_19